Zoran Zdraveski
Net worth: 3 504 $ as of 2026-07-30
Net worth: 3 504 $ as of 2026-07-30
Zoran Zdraveski is currently Secretary, Chief Legal & Strategy Officer at TScan Therapeutics, Inc. since 2021.
Formerly, Dr. Zdraveski was Vice President & Associate General Counsel at Epizyme, Inc. from 2012 to 2017 and Secretary & Chief Legal Officer at Magenta Therapeutics, Inc. from 2017 to 2021.
Education includes undergraduate and graduate degrees from Southern Methodist University, a graduate degree from Suffolk University Law School conferred in 2007, and a doctorate from the Massachusetts Institute of Technology conferred in 2002.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-01-19 | 4,716 ( 0.01% ) | 3 504 $ | 2026-07-30 |
| Companies | Position | Start |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | General Counsel | 2021-09-08 |
| Companies | Position | End |
|---|---|---|
| MAGENTA THERAPEUTICS | General Counsel | 2021-03-31 |
| EPIZYME, INC. | Corporate Officer/Principal | 2017-03-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 6 |
|---|---|
Southern Methodist University
Southern Methodist University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Develops therapeutics for the treatment of patients with genetically defined cancers | Health Technology |
Suffolk University Law School
Suffolk University Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Magenta Therapeutics, Inc.
Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures novel medicines | Health Technology |
TScan Therapeutics, Inc.
TScan Therapeutics, Inc. BiotechnologyHealth Technology Develops T-cell therapies for cancer patients | Health Technology |
Select your edition
All financial news and data tailored to specific country editions